Physician profile
Jill Tolia
NPI 1972721629
$1,443.85
in general payments reported to CMS, 2019-2025
12 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2022: $657 · 2023: $141 · 2024: $284 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634 · Education: $38.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.19 |
| Education | $38.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $466.89 | 2022-2025 | Nuzyra |
| Insmed, INC. | $262.97 | 2023-2025 | Arikayce |
| Gilead Sciences, INC. | $185.96 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $182.38 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Ferring Pharmaceuticals INC. | $161.74 | 2023-2024 | Rebyota |
| Amgen INC. | $45.21 | 2023-2024 | Prolia, Evenity |
| Viiv Healthcare Company | $34.36 | 2022 | |
| Lundbeck LLC | $27.43 | 2024 | Vyepti |
| Calliditas Therapeutics US INC. | $23.05 | 2023 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $20.66 | 2023 | |
| Janssen Pharmaceuticals, INC | $19.66 | 2022 | |
| Melinta Therapeutics, LLC | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Tolia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.